Marker Therapeutics, Inc. (MRKR): Price and Financial Metrics


Marker Therapeutics, Inc. (MRKR): $1.89

-0.03 (-1.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRKR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

MRKR Stock Summary

  • With a price/sales ratio of 207.58, Marker Therapeutics Inc has a higher such ratio than 97.79% of stocks in our set.
  • With a year-over-year growth in debt of 2,430.5%, Marker Therapeutics Inc's debt growth rate surpasses 99.15% of about US stocks.
  • As for revenue growth, note that MRKR's revenue has grown 118.95% over the past 12 months; that beats the revenue growth of 95.53% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Marker Therapeutics Inc, a group of peers worth examining would be HRTX, APTX, BCDA, RESN, and CYCN.
  • Visit MRKR's SEC page to see the company's official filings. To visit the company's web site, go to www.markertherapeutics.com.

MRKR Stock Price Chart Interactive Chart >

Price chart for MRKR

MRKR Price/Volume Stats

Current price $1.89 52-week high $3.77
Prev. close $1.91 52-week low $1.32
Day low $1.82 Volume 1,045,420
Day high $1.94 Avg. volume 3,064,974
50-day MA $2.41 Dividend yield N/A
200-day MA $1.89 Market Cap 149.49M

Marker Therapeutics, Inc. (MRKR) Company Bio


Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.


MRKR Latest News Stream


Event/Time News Detail
Loading, please wait...

MRKR Latest Social Stream


Loading social stream, please wait...

View Full MRKR Social Stream

Latest MRKR News From Around the Web

Below are the latest news stories about Marker Therapeutics Inc that investors may wish to consider to help them evaluate MRKR as an investment opportunity.

Study shows wearables could detect COVID-19 earlier

Tejaswini Mishra, PhD, Research Scientist in the Department of Genetics at Stanford University School of Medicine, joins Yahoo Finance’s Alexis Christoforous to discuss the use of wearables to detect COVID-19.

Yahoo | April 8, 2021

Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't?

Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.

Yahoo | April 7, 2021

Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the closing of an underwritten public offering of 32,282,857 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Marker from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $56.5 million.

Yahoo | March 16, 2021

Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:10 p.m. ET.

Yahoo | March 15, 2021

Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has treated the first patient in the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate. The trial is enrolling patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings.

Yahoo | March 3, 2021

Read More 'MRKR' Stories Here

MRKR Price Returns

1-mo -21.90%
3-mo -14.09%
6-mo 16.67%
1-year -10.85%
3-year -35.05%
5-year -74.39%
YTD 30.34%
2020 -49.65%
2019 -48.11%
2018 41.58%
2017 1.03%
2016 -46.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0188 seconds.